Travoprost Five Day Posology Study

Completed · Phase 2

Conditions studied: Open-angle Glaucoma (OAG), Ocular Hypertension

In brief

The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.

Key facts

Study ID

NCT01114893

Run by

Alcon Research

People needed

60

Starts

2010-04-01

Last updated by the study team

2011-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• either sex and any race/ethnicity, ≥18 years old
• diagnosed with open-angle glaucoma, and/or ocular hypertension
• meets the following IOP entry criteria:
• Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1
• Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day 0), and at 8 AM on Day 1
• satisfies all informed consent requirements; able to read, sign and date the informed consent

You may not qualify if…

• females of childbearing potential not meeting protocol conditions
• angle grade less than Grade 2 in either eye
• cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye
• severe central visual field loss in either eye
• any abnormality preventing reliable applanation tonometry in either eye
• hypersensitivity to prostaglandin analogues or to any component of the study medication

Where it is running

• Contact Alcon Call Center For Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.